ICU Medical reported second-quarter results that surpassed Wall Street expectations and issued full-year adjusted EPS guidance above analyst estimates. Revenue rose 1.5% year-on-year to $551.7 million, beating the consensus of $532.8 million. Adjusted EPS came in at $2.37, 23.8% above the $1.91 estimate, while adjusted EBITDA of $110 million exceeded the $101.1 million forecast. The company guided for full-year adjusted EPS of $8.80 at the midpoint, topping analyst projections by 7.8%, and full-year EBITDA of $425 million, above the $417 million consensus.
ICU Medical IncICU Medical beat Q2 estimates and raised full-year EPS guidance, exceeding analyst expectations.
